Avelumab and Merkel Cell Carcinoma: Examining Biological Plausibility and Causation

From General Health Literacy to Occupational Exposure Concerns

The legacy context of general health and science information emphasizes broad wellness principles, patient-centered care, and the integration of emerging biomedical knowledge into routine practice. This foundation, rooted in accessible medical communication and preventive health strategies, naturally extends to understanding how therapeutic interventions may influence disease risk. Within this framework, the transition from general health awareness to specific occupational exposure concerns becomes a matter of refining focus: moving from population-level health guidance to the nuanced evaluation of pharmaceutical agents in clinical and manufacturing settings. Avelumab, a monoclonal antibody used in oncology, represents a point where therapeutic benefit and potential risk intersect. In mass production environments, workers may encounter avelumab or its precursors, raising questions about exposure pathways and long-term health implications. The biological plausibility of avelumab-related Merkel cell carcinoma risk emerges from the drug's mechanism of action—immune checkpoint inhibition—which, while therapeutic in cancer patients, could theoretically alter immune surveillance in exposed individuals. This pivot from general health literacy to occupational hazard assessment requires careful consideration of dose, duration, and individual susceptibility, without invoking unsubstantiated mechanistic claims. The transition thus reframes the legacy heritage of health information into a targeted inquiry about workplace safety and pharmaceutical stewardship.

Biological Plausibility: Mechanism of Action and Evidence Review

Avelumab is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096). It is approved in the USA, the EU, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis (https://pubmed.ncbi.nlm.nih.gov/33439294; https://pubmed.ncbi.nlm.nih.gov/29799096). The approval was based on the JAVELIN Merkel 200 phase II trial, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC treated with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096). However, the relationship between avelumab and MCC causation requires careful examination of biological plausibility, risk communication, and temporal considerations. MCC arises from two primary etiologies: approximately 80% of cases are driven by the human Merkel cell polyomavirus (MCPyV), while the remaining 20% are induced by ultraviolet light, leading to a high mutational burden (https://pubmed.ncbi.nlm.nih.gov/34445385). Avelumab, as an anti-PD-L1 inhibitor, works by blocking the PD-1/PD-L1 interaction, thereby enhancing T-cell responses against tumor cells (https://pubmed.ncbi.nlm.nih.gov/34445385). This mechanism is therapeutic in MCC, as immune checkpoint inhibitors (ICIs) like avelumab show better overall response rates and longer duration of responses compared to conventional chemotherapy (https://pubmed.ncbi.nlm.nih.gov/34445385). However, ICIs are also known to cause overactivation of the immune system, leading to immune-related adverse events (irAEs) (https://pubmed.ncbi.nlm.nih.gov/31543781). These irAEs can include reactivation of underlying conditions, such as sarcoidosis, as reported in a case of hypercalcemia during avelumab treatment for metastatic MCC (https://pubmed.ncbi.nlm.nih.gov/31543781). The question of whether avelumab can cause de novo MCC is not supported by the available evidence. Instead, the literature describes avelumab as a treatment for existing MCC, not as a causative agent. The biological plausibility for avelumab-related MCC causation would require a mechanism by which PD-L1 inhibition induces malignant transformation of Merkel cells. No such mechanism is documented in the provided evidence. In fact, the evidence indicates that avelumab is used to treat MCC, and that patients who become refractory to avelumab may respond to other ICI combinations, such as ipilimumab plus nivolumab (https://pubmed.ncbi.nlm.nih.gov/33439294; https://pubmed.ncbi.nlm.nih.gov/36450381). This suggests that avelumab does not initiate MCC but rather modulates the immune response to an existing tumor.

Risk Communication, Warnings, and Temporal Considerations

The adequacy of warnings regarding avelumab and MCC is addressed in the prescribing information and clinical literature. Avelumab is specifically approved for metastatic MCC, and its use is associated with irAEs, which are well-documented (https://pubmed.ncbi.nlm.nih.gov/31543781). However, the evidence does not indicate that avelumab carries a warning for causing MCC. Instead, the risk is that avelumab may not be effective in all patients; approximately 50% of patients do not respond or develop irAEs due to mechanisms such as down-regulation of MHC complexes or induction of anti-inflammatory cytokines (https://pubmed.ncbi.nlm.nih.gov/34445385). For affected patients, the primary causation-related consideration is whether avelumab treatment led to progression of pre-existing MCC or to irAEs that mimic or complicate MCC. The evidence shows that avelumab-refractory patients may have limited treatment options, but combined ipilimumab/nivolumab can be effective in some cases (https://pubmed.ncbi.nlm.nih.gov/33439294; https://pubmed.ncbi.nlm.nih.gov/36450381). The timeline between avelumab exposure and documented harm is relevant for patients who develop adverse events during treatment. In the JAVELIN Merkel 200 trial, responses were assessed over time, and irAEs occurred during treatment (https://pubmed.ncbi.nlm.nih.gov/29799096). For example, the case of hypercalcemia due to sarcoidosis reactivation occurred during avelumab therapy and resolved with corticosteroids, allowing continuation of avelumab (https://pubmed.ncbi.nlm.nih.gov/31543781). This indicates that adverse events can emerge weeks to months after initiation. However, no evidence links avelumab exposure to the development of new MCC. The temporal relationship between avelumab and MCC is therefore one of treatment rather than causation. Based on the provided evidence, there is no biological plausibility for avelumab causing Merkel cell carcinoma. Avelumab is a therapeutic agent for MCC, and its use is associated with immune-related adverse events but not with de novo MCC induction. Warnings appropriately address irAEs, and causation considerations for affected patients focus on treatment response and adverse event management. The timeline between avelumab exposure and harm is consistent with known irAE profiles, not with MCC development.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

Can avelumab cause Merkel cell carcinoma?

No, the available evidence does not support that avelumab causes Merkel cell carcinoma. Avelumab is a treatment for existing MCC, and its mechanism of action as an immune checkpoint inhibitor does not induce malignant transformation of Merkel cells. Studies show avelumab is used to treat MCC, not cause it (https://pubmed.ncbi.nlm.nih.gov/29799096; https://pubmed.ncbi.nlm.nih.gov/34445385).

What are the risks of avelumab exposure in occupational settings?

Occupational exposure to avelumab may pose risks of immune-related adverse events, similar to those seen in patients, such as overactivation of the immune system. However, there is no evidence linking avelumab exposure to the development of new Merkel cell carcinoma. Proper handling and safety protocols are recommended to minimize exposure (https://pubmed.ncbi.nlm.nih.gov/31543781).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel Cell Carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Check Whether Your Situation Qualifies

Free and confidential. No obligation — an initial records screening only.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.